奥沙利铂联合卡培他滨行新辅助化疗治疗进展期胃癌30例疗效观察.doc

奥沙利铂联合卡培他滨行新辅助化疗治疗进展期胃癌30例疗效观察[摘要] 目的 探讨奥沙利铂联合卡培他滨行新辅助化疗治疗进展期胃癌的疗效。方法 60例进展期胃癌患者分为对照组和观察组各30例，对照组采用ECF化疗方案进行围手术期化疗，观察组采用奥沙利铂联合卡培他滨进行围手术期化疗。结果 观察组总有效率高于对照组，但无显著性差异（P＞0.05）；观察组骨髓抑制、胃肠道反应发生率低于对照组（P＜0.05）；两组患者达到根治效果（D2+ D1）的比率有显著性差异（P＜0.05），两组1年生存率有显著性差异（P＜0.05），观察组均高于对照组。结论 奥沙利铂联合卡培他滨对进展期胃癌行围手术期化疗，其术前化疗总有效率、肿瘤手术切除率、根治切除率、患者1年生存率均高于ECF化疗方案，毒副反应显著低于ECF化疗方案。 [关键词]进展期胃癌；新辅助化疗；5-氟尿嘧啶；卡培他滨；奥沙利铂 [中图分类号] R735.2[文献标识码] B [文章编号] 1673-9701（2011）21-61-02 Oxaliplatin Combined with Capecitabine Neoadjuvant Chemotherapy Line Treatment of Advanced Gastric Cancer：An Effect Observation of 30 Cases FU Jiong General Surgery and Oncology Department，Fenghua City People’s Hospital，Fenghua 315500，China [Abstract] Objective Capecitabine combined with oxaliplatin neoadjuvant chemotherapy line treatment of advanced gastric cancer patients. Methods Sixty patients with advanced gastric cancer patients were divided into control group and observation group of 30 patients in the control group were treated with chemotherapy regimen ECF perioperative chemotherapy group were observed with oxaliplatin combined with capecitabine for perioperative chemotherapy. ResultsThe total effective rate higher than observed， but no significant difference（P＞0.05）；Observed bone marrow suppression， gastrointestinal reaction rate than the control group（P＜0.05）； two groups of patients to achieve radical results（D2+ D1） ratio was significantly different（P＜0.05），two 1-year survival was significantly different（P＜0.05），were higher than the observation group. Conclusion Oxaliplatin in combination with capecitabine in advanced gastric cancer perioperative chemotherapy，and its total effective preoperative chemotherapy， tumor resection rate，curative resection rate，1-year survival rates were higher than in patients with ECF chemotherapy， drugs， side effects was significantly lower than ECF chemotherapy. [Key words] Advanced gastric cancer；Neoadjuvant chemotherapy；5-fluorouracil； Capecitabine；Oxaliplatin 胃癌患